Skip to content

Targeting CD47-SIRPa Myeloid Checkpoint Pathway to Enhance Innate & Adaptive Immunity Against Cancer without Hematological Toxicity

Time: 9:00 am
day: Day One


• Discuss how ALX148, a unique CD47 blocker which is a high affinity SIRPa fusion protein linked to an inactive Fc region of human immunoglobulin, is designed to maximize the clinical benefit of antibody-based therapies and its clinical development for a broad range of tumor types
• Review preclinical studies where ALX148 bridges innate and adaptive immunity via Fc-dependent and Fc-independent mechanisms to enhance anti-tumor response in combination with targeted anti-cancer antibodies and checkpoint inhibitors with no adverse effect on CD47-expressing normal blood cells
• Understand how ALX148 is well tolerated and demonstrates antibody-like PK and complete CD47 target occupancy in cancer patients
• Discuss anti-cancer activity and translational results from Phase 1 program